 "Lupin gains on tentative approval for generic Epzicom tablets")
Lupin gained 4% to Rs 1,470 on the National Stock Exchange (NSE) after the company announced that it received tentative approval for generic Epzicom tablets.
“The company has received tentative approval for its Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg from the United State Food and Drug Administration (USFDA) to market a generic version of ViiV Healthcare Company’s Epzicom tablets, 600 mg/300 mg,” Lupin said in a press release.
Lupin’s Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Epzicom tablets had US sales of $426 million, according to IMS Mat September 2016.
At 12:30 pm, the stock was up 3.5% at Rs 1,463 on the NSE as compared to 0.02% rise in the Nifty50 index. A combined 773,774 shares changed hands on the counter on BSE and NSE so far.
“The company has received tentative approval for its Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg from the United State Food and Drug Administration (USFDA) to market a generic version of ViiV Healthcare Company’s Epzicom tablets, 600 mg/300 mg,” Lupin said in a press release.
Lupin’s Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Epzicom tablets had US sales of $426 million, according to IMS Mat September 2016.
At 12:30 pm, the stock was up 3.5% at Rs 1,463 on the NSE as compared to 0.02% rise in the Nifty50 index. A combined 773,774 shares changed hands on the counter on BSE and NSE so far.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%